Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors

Among the recent advances in the molecular targeted therapy of cancer, the applications focused on epidermal growth factor receptor (EGFR) are currently the most promising and the most advanced at clinical level. In view of the different modes of action of monoclonal antibodies and tyrosine kinase i...

Descripción completa

Detalles Bibliográficos
Autores principales: Fischel, J-L, Formento, P, Milano, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361947/
https://www.ncbi.nlm.nih.gov/pubmed/15756277
http://dx.doi.org/10.1038/sj.bjc.6602428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361947/
https://www.ncbi.nlm.nih.gov/pubmed/15756277
http://dx.doi.org/10.1038/sj.bjc.6602428

Ejemplares similares